187 related articles for article (PubMed ID: 36688904)
1. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
[TBL] [Abstract][Full Text] [Related]
2. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract][Full Text] [Related]
3. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
Lin J; Wang W; Lin J; Chen R; Cao Y
J Cell Mol Med; 2022 Oct; 26(20):5326-5329. PubMed ID: 36102237
[TBL] [Abstract][Full Text] [Related]
4. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
5. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
7. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
[TBL] [Abstract][Full Text] [Related]
8. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
Gonzalez-Mosquera LF; Rous FA; Rogers A; Smith N; Goyert G; Gadgeel S
Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
Gu R; Shi Z; Duan T; Song M
Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
11. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract][Full Text] [Related]
12. Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.
Sentana-Lledo D; Viray H; Piper-Vallillo AJ; Widick P; Rangachari D; Wilson JL; Gangadharan SP; Aronovitz JA; Berman SM; VanderLaan PA; Costa DB
Lung Cancer; 2022 Oct; 172():124-126. PubMed ID: 36075183
[TBL] [Abstract][Full Text] [Related]
13. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract][Full Text] [Related]
14. Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results.
Lococo F; Cancellieri A; Chiappetta M; Leonetti A; Cardillo G; Zanelli F; Mangiameli G; Toschi L; Guggino G; Romano FJ; Leuzzi G; Proto C; Spaggiari L; De Marinis F; Vita E; Ampollini L; Margaritora S; Tiseo M; Bria E
Clin Lung Cancer; 2023 Jul; 24(5):467-473. PubMed ID: 37061413
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
Li J; Liu J; Zhang G; Hu W; Wang X; Liu J
Am J Case Rep; 2023 Nov; 24():e942150. PubMed ID: 37934724
[TBL] [Abstract][Full Text] [Related]
16. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
[TBL] [Abstract][Full Text] [Related]
17. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
Leonetti A; Minari R; Boni L; Gnetti L; Verzè M; Ventura L; Musini L; Tognetto M; Tiseo M
Clin Lung Cancer; 2021 Sep; 22(5):473-477. PubMed ID: 33762169
[TBL] [Abstract][Full Text] [Related]
18. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
19. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
[TBL] [Abstract][Full Text] [Related]
20. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
